Tirzepatide in Obesity-Driven Endometrial Cancer

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Jul 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called tirzepatide to see if it can help slow down or stop the growth of endometrial cancer, which is a type of cancer that starts in the lining of the uterus. This cancer is often linked to obesity, and tirzepatide may work by helping people lose weight and by directly affecting the cancer cells. The study will look at tissue samples from the uterus before and after treatment with tirzepatide to understand its effects better.

Women who have been diagnosed with early-stage endometrial cancer and have a body mass index (BMI) of 30 or higher may be eligible to join. Participants will need to be planning to have surgery to remove their uterus and agree to follow the study’s visits and tests, including providing tissue samples before and after treatment. The trial is not yet recruiting, and it is designed for adults who are generally in good health besides their cancer diagnosis. This study offers a chance to explore a new treatment that targets both weight and cancer growth, which could be important for women facing this condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Current diagnosis of endometrioid histology cancer and scheduled to undergo hysterectomy and staging.
• • Agree to comply with all required study assessments and visits including internet capabilities.
• • Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
• • Age ≥ 18 at the time of consent.
• • Body mass index of ≥30 kg/m2.
• • Presumed clinically early-stage disease (disease confined to uterus only).
• • ECOG ≤ 2 or Karnofsky Performance Status of \> 50
• Exclusion Criteria:
• • Active infection requiring systemic therapy.
• • Subject is pregnant or breast feeding.
• • Taking any prescription medications or other drugs that may influence metabolism per discretion of investigator.
• • Taking a central nervous system stimulant.
• • Current psychological conditions that would be incompatible with participation in this study, as determined by investigator.
• • Known sensitivities (i.e., urticaria and eczema) to GIP and GLP-1 receptor agonists.
• • Have type 1 diabetes mellitus or latent autoimmune diabetes in adults or receiving treatment with insulin.
• • Have a history of severe hypoglycemia or not be able to communicate an understanding of hypoglycemic symptoms.